Dolsten Mikael

SEC source: 0001090872-26-000065 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,923.68

F1 · balance_after: Includes 9.295 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan in transactions exempt under Rule 16a-11. The reporting person has elected to defer these shares of common stock.

SEC source: 0001140361-26-027679 · form4.xml · derivative · entry 2

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,860

Underlying: Common Stock · 64,860 shares

Expires 2036-06-18

F2 · derivative.exercise_date: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

SEC source: 0001140361-26-027679 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,082

F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.

F2 · kind: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

F2 · price: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

SEC source: 0001090872-26-000057 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,548.385

F1 · balance_after: Includes 10.175 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan in transactions exempt under Rule 16a-11. The reporting person has elected to defer these shares of common stock.

SEC source: 0001193125-26-224624 · ownership.xml · derivative · entry 3

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,135 shares

Expires not disclosed

F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

SEC source: 0001193125-26-224624 · ownership.xml · nonDerivative · entry 2

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

SEC source: 0001193125-26-224624 · ownership.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),

F2 · kind: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,

F3 · kind: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),

F2 · price: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,

F3 · price: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

SEC source: 0001090872-26-000027 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,138.21

F1 · price: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of 1,079 shares of common stock.

F2 · balance_after: 7.182 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.

SEC source: 0001492422-26-000092 · form4.xml · derivative · entry 2

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,135

Underlying: Common Stock · 24,135 shares

Expires 2036-02-27

F2 · derivative.exercise_date: This represents a stock option award granted February 27, 2026 that vest 1/3rd per year over a three-year period subject to continued service.

SEC source: 0001492422-26-000092 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,312

F1 · kind: This restricted stock unit was granted on February 27, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.

SEC source: 0001090872-25-000083 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,973.028

F1 · price: The weighted average sale price is $149.812 with a range of $149.80 to $149.84. The Reporting Person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes 23.092 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan in transactions exempt under Rule 16a-11. The reporting person has elected to defer these shares of common stock.

SEC source: 0001140361-25-026409 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,220

F1 · security: Holdings include 14,220 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis held by the Reporting Person which cliff vest on December 31, 2025.

F2 · kind: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.

F2 · price: Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.

SEC source: 0001127602-25-009721 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,549.936

F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of 909.5 shares of common stock.

F2 · balance_after: 19.738 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.

SEC source: 0001140361-25-015425 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,220

F1 · security: Represent restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will become fully vested on December 31, 2025.

F2 · kind: Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, effective March 3, 2025, for services related to the Company's research and development activities. As part of the compensation for services rendered, the Reporting Person received $125,000 of RSUs valued based on the closing price of the Company's common stock on March 3, 2025, which will cliff vest on December 31, 2025.

SEC source: 0001225208-24-008704 · doc4.xml · derivative · entry 4

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,794

Underlying: Common Stock · 126,794 shares

Expires 2029-02-24

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

F2 · derivative.expiration_date: Reflects a modification to the settlement date of the Modified TSRUs pursuant to the Modification Offer. The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008704 · doc4.xml · derivative · entry 3

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 126,794 shares

Expires 2027-02-24

SEC source: 0001225208-24-008704 · doc4.xml · derivative · entry 2

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,760

Underlying: Common Stock · 137,760 shares

Expires 2030-02-23

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

F2 · derivative.expiration_date: Reflects a modification to the settlement date of the Modified TSRUs pursuant to the Modification Offer. The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008704 · doc4.xml · derivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 137,760 shares

Expires 2028-02-23

SEC source: 0001140361-24-040838 · form4.xml · derivative · entry 2

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,988

Underlying: Common Stock · 22,988 shares

Expires 2034-09-09

F2 · derivative.exercise_date: This option represents a right to purchase a total of 22,988 shares of the Issuer's common stock, which will fully vest on September 9, 2025.

SEC source: 0001140361-24-040838 · form4.xml · derivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,545

Underlying: Common Stock · 27,545 shares

Expires 2034-09-09

F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,545 shares of the Issuer's common stock, which will vest in equal monthly installments over a three-year period, such that all of the shares underlying this option will be fully vested on September 9, 2027.

SEC source: 0001127602-24-010682 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,711.198

F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of 839 shares of common stock.

F2 · balance_after: 15.196 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.

SEC source: 0001225208-24-003244 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 321,729

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-24-003204 · doc4.xml · derivative · entry 2

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,867

Underlying: Common Stock · 189,867 shares

Expires 2031-02-27

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-24-003204 · doc4.xml · derivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,880

Underlying: Common Stock · 214,880 shares

Expires 2029-02-27

F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-24-003051 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,166

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-23-011271 · doc4.xml · derivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,581

Underlying: Common Stock · 37,552 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · shares: This transaction constitutes an intra-plan transfer to acquire Pfizer stock units in the Pfizer stock unit fund under the Pfizer Inc. Deferred Compensation Plan.

F3 · derivative.exercise_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F3 · derivative.expiration_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0000899243-23-009221 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,018.002

F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of 829 shares of common stock.

F2 · balance_after: 7.564 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.

SEC source: 0001225208-23-002917 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,145

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon).

F2 · price: Price is the closing price of Pfizer common stock on February 24, 2023.

SEC source: 0001225208-23-002811 · doc4.xml · derivative · entry 4

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,894

Underlying: Common Stock · 119,894 shares

Expires 2030-02-23

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-23-002811 · doc4.xml · derivative · entry 3

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,760

Underlying: Common Stock · 137,760 shares

Expires 2028-02-23

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-23-002811 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,223

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-22-011483 · doc4.xml · derivative · entry 5

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 133,430 shares

Expires 2026-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-22-011483 · doc4.xml · derivative · entry 4

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 127,146 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-22-011483 · doc4.xml · nonDerivative · entry 2

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 420,007

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $45.07)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.

SEC source: 0001225208-22-011483 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,837

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $45.07)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.

SEC source: 0001225208-22-006909 · doc4.xml · derivative · entry 8

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,380

Underlying: Common Stock · 15,167 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · shares: This transaction constitutes an intra-plan transfer into the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan.

F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 6

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,342

SEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 5

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 365,357

SEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 4

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,919

SEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 3

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,795

SEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 2

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,686

SEC source: 0001225208-22-006909 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 397,044

SEC source: 0001127602-22-010048 · form4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,352.438

F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of 892 shares of common stock.

F2 · balance_after: 0.438 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.

SEC source: 0001225208-22-004229 · doc4.xml · derivative · entry 5

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 158,331 shares

Expires 2024-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-22-004229 · doc4.xml · derivative · entry 4

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 127,674 shares

Expires 2024-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-22-004229 · doc4.xml · nonDerivative · entry 2

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,578

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $49.36)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.

SEC source: 0001225208-22-004229 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $49.36)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.

SEC source: 0001225208-22-003662 · doc4.xml · nonDerivative · entry 1

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,118

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon).

F2 · price: Price is the closing price of Pfizer common stock on February 25, 2022.

SEC source: 0001225208-22-003473 · doc4.xml · derivative · entry 4

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,516

Underlying: Common Stock · 111,516 shares

Expires 2029-02-24

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-22-003473 · doc4.xml · derivative · entry 3

Dolsten Mikael · CIK 0001437590 · President R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,794

Underlying: Common Stock · 126,794 shares

Expires 2027-02-24

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.